Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 92 peer-reviewed journal articles Updated
Nephrology · Membranous Nephropathy

Membranous Nephropathy (Membranous Glomerulonephritis): A Patient Guide

At a Glance

Membranous nephropathy can cause heavy protein loss, swelling, and blood-clot risk. Doctors first look for secondary causes, then use supportive care and risk-based immune treatment while monitoring kidney function, urine protein, and antibody levels.

Membranous nephropathy (also called membranous glomerulonephritis) is a rare immune-deposit pattern of kidney disease. In this condition, your immune system mistakenly produces antibodies that attack the podocytes, which are the specialized cells that form the “mesh” of your kidney’s filters. As these filters become damaged and “leaky,” large amounts of vital proteins escape from your blood into your urine, leading to a cluster of symptoms known as nephrotic syndrome, including significant swelling and high cholesterol [1][2]. Primary MN is an autoimmune disease, while secondary MN is associated with systemic disease.

Navigating this diagnosis is often a marathon rather than a sprint. Because some patients experience a spontaneous remission—meaning the disease goes away on its own—doctors do not always start aggressive treatments immediately. Instead, they use risk stratification to carefully monitor your kidney function and protein levels, matching the intensity of treatment to the severity of your case [3][4]. For many, the first line of defense is supportive care, which involves using blood pressure medications and a low-sodium diet to physically reduce the pressure on your kidney filters and lower the protein leak [5].

Before starting powerful immune-suppressing drugs, it is essential to undergo a secondary evaluation. This is a thorough search to evaluate if the kidney disease is being associated with an underlying issue like a hidden cancer, a chronic infection, or another autoimmune condition such as lupus [6][7]. Identifying a secondary cause can fundamentally change your treatment path, though immune therapy may still be needed [8].

As you move through treatment, an important emergency to remain aware of is the increased risk of blood clots. Because the kidneys lose natural anti-clotting proteins in the urine, patients with membranous nephropathy are at a higher risk for deep vein thrombosis or pulmonary embolisms, especially when blood protein levels are very low [9][10]. Your care team will monitor these levels closely and may prescribe blood thinners to protect you while your kidneys are healing [11].

Healing in membranous nephropathy follows a unique timeline: the “immune fire” usually goes out months before the “smoke” of the protein leak clears. This means your lab tests may show your antibodies are gone long before your swelling subsides or your protein levels stabilize [12][13]. While relapses can occur, it is important to remember that a relapse is not a failure of treatment, but a signal that an adjustment is needed [14]. With modern management and careful monitoring, the vast majority of patients are able to preserve their kidney function and lead full, active lives [15].

In this guide

6 chapters

01

Understanding Your Diagnosis: Membranous Nephropathy

Learn what membranous nephropathy means, including nephrotic syndrome, emergency warning signs, remission, and treatment decisions for your care today.

02

Subtypes and Diagnosis: Finding the Cause

Learn how membranous nephropathy is diagnosed, including primary and secondary causes, anti-PLA2R blood tests, kidney biopsy, and pathology report findings.

03

Living with Symptoms: Supportive Care and Safety

Learn how supportive care for membranous nephropathy manages swelling, protein loss, blood-clot risk, cholesterol, sodium, and medication safety at home.

04

Treatment Options and the Road to Recovery

Learn how membranous nephropathy treatment is chosen by risk, including rituximab, calcineurin inhibitors, cyclophosphamide, and the timeline for remission.

05

Building Your Care Team: Specialists and Screenings

Learn how to build a membranous nephropathy care team, identify secondary causes, complete cancer and autoimmune screening, and prepare for immune treatment.

06

The Long-Term Outlook: Monitoring and Relapse

Learn how membranous nephropathy relapse is monitored with urine protein, anti-PLA2R, albumin, eGFR, and blood pressure, plus your long-term kidney outlook.

Common questions in this guide

What is membranous nephropathy?
Membranous nephropathy is a kidney disease in which the immune system makes antibodies that damage specialized cells in the kidney filters. The damaged filters let too much protein enter the urine, which can cause swelling and high cholesterol. It may occur on its own or be linked to another condition.
Is membranous nephropathy the same as membranous glomerulonephritis?
Yes. Membranous glomerulonephritis is another name for membranous nephropathy. Both terms describe the same immune-related pattern of damage in the kidney filters.
How is membranous nephropathy treated?
Treatment depends on the risk of kidney damage and whether the disease may improve on its own. Supportive care can include blood pressure medicine, a low-sodium diet, and close monitoring; people at higher risk may need immune-suppressing treatment. Blood thinners may be considered when the risk of blood clots is high.
Why do doctors look for a secondary cause of membranous nephropathy?
Some cases are linked to an underlying problem such as cancer, a chronic infection, or an autoimmune disease such as lupus. Finding one of these causes can change the treatment plan, so doctors may perform a thorough secondary evaluation before starting strong immune-suppressing medicines.
How long does it take for membranous nephropathy treatment to work?
Improvement often happens in stages. Antibody activity may settle months before the protein leak, swelling, and urine tests improve, so your care team may continue monitoring kidney function, urine protein, and antibody levels even after early signs of improvement.
Does membranous nephropathy increase the risk of blood clots?
Yes. Protein loss in the urine can remove natural anti-clotting proteins from the blood, especially when blood protein levels are very low. Your care team may monitor this risk closely and prescribe a blood thinner when the potential benefit outweighs the risks.
Can membranous nephropathy go away on its own?
Some people have a spontaneous remission, meaning the disease improves without aggressive treatment. Relapses can happen, but a relapse does not necessarily mean treatment failed; it may mean that the monitoring or treatment plan needs to be adjusted.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on membranous glomerulonephritis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my blood work and biopsy, do I have the primary or secondary form of this disease?
  2. 2.Am I currently in a high-risk category for blood clots, and what precautions should I take?
  3. 3.If we decide to wait for spontaneous remission, how frequently will my protein and antibody levels be monitored?
  4. 4.What is our plan for a 'secondary evaluation' to rule out other causes like cancer or autoimmune disease?
  5. 5.What are the first signs that the treatment is working, and how long should I expect to wait to see them?

References

References (15)
  1. 1

    Membranous glomerulonephritis: histological and serological features to differentiate cancer-related and non-related forms.

    Murtas C, Ghiggeri GM

    Journal of nephrology 2016; (29(4)):469-78 doi:10.1007/s40620-016-0268-7.

    PMID: 26810113
  2. 2

    Membranous Nephropathy: Updates on Management.

    Bharati J, Waguespack DR, Beck LH

    Advances in kidney disease and health 2024; (31(4)):299-308 doi:10.1053/j.akdh.2024.04.004.

    PMID: 39084755
  3. 3

    Primary Membranous Nephropathy.

    Couser WG

    Clinical journal of the American Society of Nephrology : CJASN 2017; (12(6)):983-997 doi:10.2215/CJN.11761116.

    PMID: 28550082
  4. 4

    Contemporary review of primary membranous nephropathy.

    Filippone EJ, Farber JL

    Frontiers in immunology 2026; (17()):1836347 doi:10.3389/fimmu.2026.1836347.

    PMID: 42404886
  5. 5

    Membranous nephropathy: a review on the pathogenesis, diagnosis, and treatment.

    Lai WL, Yeh TH, Chen PM, et al.

    Journal of the Formosan Medical Association = Taiwan yi zhi 2015; (114(2)):102-11.

    PMID: 25558821
  6. 6

    Drug-Induced Membranous Nephropathy: Piecing Together Clues to Understand Disease Mechanisms.

    Avasare RS, Andeen NK, Al-Rabadi LF, et al.

    Journal of the American Society of Nephrology : JASN 2025; (36(8)):1629-1638 doi:10.1681/ASN.0000000719.

    PMID: 40198910
  7. 7

    Exostosin 1/Exostosin 2-Associated Membranous Nephropathy.

    Sethi S, Madden BJ, Debiec H, et al.

    Journal of the American Society of Nephrology : JASN 2019; (30(6)):1123-1136 doi:10.1681/ASN.2018080852.

    PMID: 31061139
  8. 8

    Anti-PLA2R and anti-THSD7A as Diagnostic Serological Markers of Idiopathic Membranous Nephropathy: A Single Centre Study.

    Fouad MA, Mahedy AW, Mansour AE, Fouad NA

    The Egyptian journal of immunology 2020; (27(2)):1-9.

    PMID: 33548972
  9. 9

    Nephrotic syndrome-induced thromboembolism in adults.

    Al-Azzawi HF, Obi OC, Safi J, Song M

    International journal of critical illness and injury science 2016; (6(2)):85-8 doi:10.4103/2229-5151.183019.

    PMID: 27308257
  10. 10

    Recurrent venous thromboembolism in primary membranous nephropathy despite direct Xa inhibitor therapy.

    Reynolds ML, Nachman PH, Mooberry MJ, et al.

    Journal of nephrology 2019; (32(4)):669-672 doi:10.1007/s40620-018-0552-9.

    PMID: 30421320
  11. 11

    Some Points for the KDIGO 2021 Guideline for Prophylactic Anticoagulation in Membranous Nephropathy: Is It Clear Enough for Us to Follow?

    Li X, Xie X, Zhao Y, et al.

    Nephron 2023; (147(3-4)):193-198 doi:10.1159/000525913.

    PMID: 35901785
  12. 12

    Combination of Rituximab, Low-Dose Cyclophosphamide, and Prednisone for Primary Membranous Nephropathy: A Case Series With Extended Follow Up.

    Zonozi R, Laliberte K, Huizenga NR, et al.

    American journal of kidney diseases : the official journal of the National Kidney Foundation 2021; (78(6)):793-803 doi:10.1053/j.ajkd.2021.04.014.

    PMID: 34174365
  13. 13

    Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy.

    Ruggenenti P, Debiec H, Ruggiero B, et al.

    Journal of the American Society of Nephrology : JASN 2015; (26(10)):2545-58 doi:10.1681/ASN.2014070640.

    PMID: 25804280
  14. 14

    Primary membranous nephropathy in the Italian region of Emilia Romagna: results of a multicenter study with extended follow-up.

    Albertazzi V, Fontana F, Giberti S, et al.

    Journal of nephrology 2024; (37(2)):471-482 doi:10.1007/s40620-023-01803-9.

    PMID: 37957455
  15. 15

    Anti-PLA2R Antibodies as a Prognostic Factor in PLA2R-Related Membranous Nephropathy.

    Timmermans SA, Abdul Hamid MA, Cohen Tervaert JW, et al.

    American journal of nephrology 2015; (42(1)):70-7 doi:10.1159/000437236.

    PMID: 26344651

This page about membranous nephropathy is for informational purposes only and does not constitute medical advice. Your nephrologist or care team should interpret your results and advise you about monitoring, clot prevention, and treatment.